Increasing doxorubicin activity against breast cancer cells using <scp>PPAR</scp>γ‐ligands and by exploiting circadian rhythms

Abstract

Our data show, for the first time, that circadian rhythms play an important role in doxorubicin toxicity in the myocardium; doxorubicin should be administered mid-morning, when circulating levels of melatonin are low, and in combination with rosiglitazone to increase therapeutic efficacy in cancer cells while reducing the toxic effects on the heart.